Avid Bioservices Inc (CDMO)

[biopharm]

"We are pleased with the initial results we have seen from this clinical study evaluating the combination of bavituximab with an established antiviral drug in HCV patients. We see good evidence that the combination of bavituximab with ribavirin has a better safety profile than an interferon containing regimen which was one of the primary objectives of the study," said Joseph S. Shan, vice president of clinical and regulatory affairs at Peregrine Pharmaceuticals.

For those that like to keep track.... BOD changes from 2014 to 2016 and still waiting on the full list of speakers and all topics.

Board of Directors, ICDS - Feb 2014

Patrizia Agostinis; Raymond Birge; Christoph Borner; Marianne Cronje; Katharina D’Herde; Devrim Gozuacik; Roya Khosravi-Far; Simone Fulda; Nader Maghsoudi; Seamus Martin; Soraya Smaili; Eileen White; Junying Yuan; Zahra Zakeri

Changes as of Feb 20, 2016
Outgoing: Seamus Martin
New Additions: Eli Arama, Francesco Cecconi, Tom Cotter

ICDS Advisory Board - Feb 20, 2016

Douglas Green; Marie-Lise Gougeon; Michael Hengartner; H. Robert Horvitz; Marja Jäättelä; Adi Kimchi;Sharad Kumar; Sergio Lavandero; Richard A. Lockshin; Carlos Martínez; Shigekazu Nagata; Don Nicholson; Mauro Piacentini; Jun-Ying Yuan; Boris Zhivotovsky

http://www.celldeath-apoptosis.org/oursoci/board-of-directors.html

--------------------------------------------------------

CHAIRS

Eli Arama (Israel)

Ray Birge, ( U.S.A):

Dhyan Chandra, (USA)

Jerry Chipuk, (U.S.A)

Marianne Cronje (South Africa)

Devrim Gozuacik, (Turkey):

Annie Joubert, (South Africa):

Samuel Katz (U.S.A)

Zahra Zakeri, (USA)



PARTIAL LIST OF SPEAKERS (Alphabetical order)

Eli Arama (Israel): Move or Die: Linking caspases and cell migration and invasion in Drosophila

Frank-Dietmar Böhmer (Germany ) : Redox regulation of FLT3ITD signaling in cells of Acute Myeloid Leukemia

Rolf Brekken, (USA): blockade of phosphatidylserine and immune activation in cancer’

Marcos A. Carpio: (U.S.A): TBA

Tom Cotter ( Ireland): TBA

Marc Diederich, (Luxemberg ): Cardenolides trigger mitophagy, apoptosis or necroptsis in human neuroblastoma

Zvi Fishelson, (Israel): Activators and inhibitors of programmed necrotic cell death induced by the complement C5b-9 complex

Simone Fulda, (Germany): Novel opportunities for exploiting programmed cell death pathways for cancer therapy

Adrienne Gorman, (Ireland): TBA

Atan Gross (Israel): Importance of mitochondria metabolism for regulating the DNA damage response in hematopoietic stem cells

William Kaiser, (U.S.A): Death’s trap door: necroptosis in host defense

Sarit Larisch, (Israel): ARTS initiates apoptosis by regulating XIAP and Bcl-2 family members

Seamus Martin (Ireland): Cell Death: An Inflammatory Perspective'

Triona Ni Chonghaile, (Ireland):Determining Mitochondria's Distance to Death's Door

Erik Norberg, (Sweden): Profiling and Targeting of Tumor Metabolism

Helin Norberg, (Sweden): CMA, Metabolic catastrophe and Cell Death

Benedicte Py. (France):Regulation of the NLRP3 inflammasome by post-translational modifications

Hermann Steller (USA): Regulation of apoptosis in development, stem cells and cancer

Alex Tonks (UK): The role of reactive oxygen species in acute myeloid leukaemia; cell death, proliferation and metabolism

Boris Zhivotovsky, (Sweden): miRNAs' role in sensitivity of lung adenocarcinoma to treatment

http://www.celldeath-apoptosis.org/extensions/templates/beez5/next-meeting-html/typography-beez-5/speakers-topics.html

--------------------------------------------------

Tom Cotter:

Research Interests

The main research focus in the Cotter Laboratory is in understanding the role of cell signalling pathways, in particular those that are redox regulated and active, in tumour cell survival and in degenerative conditions of the retina. The role of reactive oxygen species such as hydrogen peroxide has undergone a renaissance in the last decade with this molecule shown to be acting as both a driver of cell death (at high concentrations) but also more significantly as a specific activator of cell survival pathways at lower concentrations.
In the case of several tumours both leukaemia and colon we see an increase in ROS production on oncogene activation. From multiphoton microscopy this increase appears to be localised to the ER and is produced by activation of one member of the NADPH Oxidase (Nox) family of enzymes. This in turn activates the Akt/PI3k pathway by the inhibition of one of several negatively regulating phosphatases. The result is a stronger tumour cell survival signal which aids tumour development and hinder chemotherapeutic treatments.In the retina our focus is also on the signalling role of ROS specifically how it contributes to post-mitotic cells cell survival either following short term stress or via growth factor signalling. This is particularly important as we strive to understand what occurs at the biochemical level during degenerative retinal diseases. We are also exploring new molecular therapies and the role played by cells such as glial cells which are not directly involved in the visual process itself, but which are none the less vital for the process.

http://publish.ucc.ie/researchprofiles/D003/tcotter

-----------------------------------------------------

Lets go Tom, Eye see you just may have been paying attention to PS Targeting and all those negative charges at the surfae. Speak... everyone speak up : ) To Ireland we go!

https://vimeo.com/62115945